Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression

被引:61
|
作者
Nicolle, Remy [1 ]
Ayadi, Mira [1 ]
Gomez-Brouchet, Anne [2 ]
Armenoult, Lucile [1 ]
Banneau, Guillaume [1 ]
Elarouci, Nabila [1 ]
Tallegas, Matthias [3 ]
Decouvelaere, Anne-Valerie [4 ,5 ]
Aubert, Sebastien [6 ]
Redini, Francoise [7 ]
Marie, Beatrice [8 ]
Labit-Bouvier, Corinne [9 ]
Reina, Nicolas [10 ]
Karanian, Marie [4 ,5 ]
Le Nail, Louis-Romee [7 ,11 ]
Anract, Philippe [12 ]
Gouin, Francois [13 ,14 ]
Larousserie, Frederique [15 ]
de Reynies, Aurelien [1 ]
de Pinieux, Gonzague [7 ,16 ]
机构
[1] Ligue Natl Canc, Programme Cartes Identite Tumeurs CIT, Paris, France
[2] Univ Toulouse, Dept Pathol, CHU Toulouse Oncopole, Toulouse, France
[3] CHRU Tours, Plateforme Genet Mol Canc, Tours, France
[4] Ctr Leon Berard, Dept Biopathol, Lyon, France
[5] Univ Claude Bernard Lyon 1, Univ Lyon, CNRS 5286, Canc Res Ctr Lyon,INSERM U1052, Lyon, France
[6] Univ Lille, Dept Pathol, CHU Lille, Lille, France
[7] Univ Nantes, UMR1238, INSERM, Sarcomes Osseux & Remodelage Tissus Calcifies,Fac, Nantes, France
[8] CHU Nancy, Dept Pathol, Nancy, France
[9] Aix Marseille Univ, CHU Marseille, Dept Pathol, INSERM,MMG, Marseille, France
[10] CHU Toulouse, Dept Orthoped Surg, Hop Pierre Paul Riquet, Toulouse, France
[11] Univ Tours, Dept Orthoped Surg, CHRU Tours, Tours, France
[12] Univ Paris 05, Sorbonne Paris Cite, Hop Cochin, AP HP,Dept Orthoped Surg, Paris, France
[13] Ctr Leon Berard, Dept Surg, Lyon, France
[14] CHU Nantes, Dept Orthopaed Surg, Nantes, France
[15] Univ Paris 05, Hop Cochin, AP HP, Serv Pathol, Paris, France
[16] Univ Tours, Dept Pathol, CHRU Tours, Tours, France
关键词
EXPRESSION; MUTATIONS;
D O I
10.1038/s41467-019-12525-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chondrosarcomas are primary cancers of cartilaginous tissue with highly contrasting prognoses. These tumors are defined by recurrent mutations in the IDH genes and other genetic alterations including inactivation of CDKN2A and COL2A1; however, these have no clinical value. Here we use multi-omics molecular profiles from a series of cartilage tumors and find an mRNA classification that identifies two subtypes of chondrosarcomas defined by a balance in tumor differentiation and cell cycle activation. The microRNA classification reveals the importance of the loss of expression of the 14q32 locus in defining the level of malignancy. Finally, DNA methylation is associated with IDH mutations. We can use the multi-omics classifications to predict outcome. We propose an mRNA-only classifier to reproduce the integrated multi-omics classification, and its application to relapsed tumor samples shows the progressive nature of the classification. Thus, it may be possible to use mRNA-based signatures to detect patients with high-risk chondrosarcomas.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Determinants of cerebral radiological progression in Fabry disease
    Korver, Simon
    Longo, Maria G. F.
    Lima, Marjana R.
    Hollak, Carla E. M.
    El Sayed, Mohamed
    van Schaik, Ivo N.
    Vedolin, Leonardo
    Dijkgraaf, Marcel G. W.
    Langeveld, Mirjam
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (07): : 756 - 763
  • [32] Exploring determinants of progression of Parkinson's disease
    Orlev, Y.
    Yahalom, G.
    Cohen, O. S.
    Inzelberg, R.
    Kozlova, E.
    Goldbourt, U.
    Hassin-Baer, S.
    MOVEMENT DISORDERS, 2013, 28 : S387 - S387
  • [33] Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression
    Xin Ku
    Jinghan Wang
    Haikuo Li
    Chen Meng
    Fang Yu
    Wenjuan Yu
    Zhongqi Li
    Ziqi Zhou
    Can Zhang
    Ying Hua
    Wei Yan
    Jie Jin
    Phenomics, 2023, 3 : 148 - 166
  • [34] The critical determinants of improvement in healthcare and lessons for integrated care
    Harnett, Patrick John
    INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2016, 16
  • [35] Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology
    K. Okrah
    S. Tarighat
    B. Liu
    H. Koeppen
    M. C. Wagle
    G. Cheng
    C. Sun
    A. Dey
    M. T. Chang
    T. Sumiyoshi
    Z. Mounir
    C. Cummings
    G. Hampton
    L. Amler
    J. Fridlyand
    P. S. Hegde
    S. J. Turley
    M. R. Lackner
    S. M. Huang
    npj Precision Oncology, 2
  • [36] Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression
    Ku, Xin
    Wang, Jinghan
    Li, Haikuo
    Meng, Chen
    Yu, Fang
    Yu, Wenjuan
    Li, Zhongqi
    Zhou, Ziqi
    Zhang, Can
    Hua, Ying
    Yan, Wei
    Jin, Jie
    PHENOMICS, 2023, 3 (02): : 148 - 166
  • [37] ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
    Romero, Atocha
    Serna-Blasco, Roberto
    Alfaro, Cristina
    Sanchez-Herrero, Estela
    Barquin, Miguel
    Carmen Turpin, Maria
    Chico, Sofia
    Sanz-Moreno, Sandra
    Rodrigez-Festa, Alejandro
    Laza-Briviesca, Raquel
    Cruz-Bermudez, Alberto
    Calvo, Virginia
    Royuela, Ana
    Provencio, Mariano
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 532 - +
  • [38] Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology
    Okrah, K.
    Tarighat, S.
    Liu, B.
    Koeppen, H.
    Wagle, M. C.
    Cheng, G.
    Sun, C.
    Dey, A.
    Chang, M. T.
    Sumiyoshi, T.
    Mounir, Z.
    Cummings, C.
    Hampton, G.
    Amler, L.
    Fridlyand, J.
    Hegde, P. S.
    Turley, S. J.
    Lackner, M. R.
    Huang, S. M.
    NPJ PRECISION ONCOLOGY, 2018, 2
  • [39] Coding Molecular Determinants of Thyroid Cancer Development and Progression
    Valvo, Veronica
    Nucera, Carmelo
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 37 - +
  • [40] Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features
    Zhaoqi Liu
    Shihua Zhang
    BMC Genomics, 16